Antibody Response of Combination of BNT162b2 and CoronaVac Platforms of COVID-19 Vaccines against Omicron Variant

Omicron Variant (B.1.1.529): Infectivity, Vaccine Breakthrough, and Antibody Resistance

(2022) Jiahui Chen et al.   Journal of Chemical Information and Modeling

Safety and immunogenicity of S-Trimer (SCB-2019), a protein subunit vaccine candidate for COVID-19 in healthy adults: a phase 1, randomised, double-blind, placebo-controlled trial

(2021) Peter Richmond et al.   LANCET

Heterologous prime-boost: Breaking the protective immune response bottleneck of COVID-19 vaccine candidates

(2021) Qian He et al.   Emerging Microbes & Infections

BNT162b2 mRNA COVID‐19 vaccine induces antibodies of broader cross‐reactivity than natural infection but recognition of mutant viruses is up to 10‐fold reduced

(2021) Xinyue Chang et al.   ALLERGY

Impact of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Variant-Associated Receptor Binding Domain (RBD) Mutations on the Susceptibility to Serum Antibodies Elicited by Coronavirus Disease 2019 (COVID-19) Infection or Vaccination

(2021) Lin-Lei Chen et al.   CLINICAL INFECTIOUS DISEASES

BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humans

(2021) Ugur Sahin et al.   NATURE

Comparative immunogenicity of mRNA and inactivated vaccines against COVID-19

(2021) Wey Wen Lim et al.   Lancet Microbe

Neutralization of Severe Acute Respiratory Syndrome Coronavirus 2 Omicron Variant by Sera From BNT162b2 or CoronaVac Vaccine Recipients

(2021) Lu Lu et al.   CLINICAL INFECTIOUS DISEASES

Omicron: Call for updated vaccines

(2021) Xingguang Li   JOURNAL OF MEDICAL VIROLOGY

Heterologous prime–boost strategies for COVID-19 vaccines

(2021) Binaya Sapkota et al.   JOURNAL OF TRAVEL MEDICINE

Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial

(2021) Alasdair P S Munro et al.   LANCET

The emergence of new SARS-CoV-2 variant (Omicron) and increasing calls for COVID-19 vaccine boosters-The debate continues

(2021) Naushad Ahmad Khan et al.   Travel Medicine and Infectious Disease

Omicron variant showed lower neutralizing sensitivity than other SARS-CoV-2 variants to immune sera elicited by vaccines after boost

(2021) Jingwen Ai et al.   Emerging Microbes & Infections

Antibody Response of BNT162b2 and CoronaVac Platforms in Recovered Individuals Previously Infected by COVID-19 against SARS-CoV-2 Wild Type and Delta Variant

(2021) Ruiqi Zhang et al.   Vaccines

Performance of a Surrogate SARS-CoV-2-Neutralizing Antibody Assay in Natural Infection and Vaccination Samples

(2021) Kwok-Hung Chan et al.   Diagnostics

Development of an inactivated vaccine candidate for SARS-CoV-2

(2020) Qiang Gao et al.   SCIENCE

Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial

(2020) Pedro M Folegatti et al.   LANCET

Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates

(2020) Edward E. Walsh et al.   NEW ENGLAND JOURNAL OF MEDICINE

Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18–59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial

(2020) Yanjun Zhang et al.   LANCET INFECTIOUS DISEASES

Heterologous prime–boost vaccination

(2009) Shan Lu   CURRENT OPINION IN IMMUNOLOGY